Recent Quotes (30 days)

You have no recent quotes
chg | %

Transition Therapeutics Inc (USA)  

(Public, NASDAQ:TTHI)   Watch this stock  
Find more results for TTHI
6.93
+0.09 (1.32%)
Real-time:   11:41AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.85 - 7.00
52 week 4.36 - 8.22
Open 6.90
Vol / Avg. 28,679.00/15,720.00
Mkt cap 243.21M
P/E     -
Div/yield     -
EPS -0.89
Shares 35.32M
Beta 0.63
Inst. own 27%
May 11, 2015
Q3 2015 Transition Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 2, 2015
Transition Therapeutics Inc at Cowen Health Care Conference - 3:30PM EST - Add to calendar
Feb 9, 2015
Q2 2015 Transition Therapeutics Inc Earnings Call
Feb 9, 2015
Q2 2015 Transition Therapeutics Inc Earnings Release
Dec 10, 2014
Transition Therapeutics Inc at Oppenheimer Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -101.88% -40.82%
Return on average equity -121.76% -47.22%
Employees 24 -
CDP Score - -

Address

101 College St Suite 220
TORONTO, ON M5G 1L7
Canada
+1-416-2607770 (Phone)
+1-416-2602886 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Transition Therapeutics Inc. (Transition) is a product-focused biopharmaceutical company developing therapeutics for disease indications with markets. The Company�s wholly-owned subsidiary, Transition Therapeutics Ireland Limited is developing CNS drug candidate ELND005 for the treatment of Alzheimer�s disease and Down syndrome. The Company�s technologies in development include ELND005 for the treatment of Alzheimer�s disease, bipolar disorder and Down syndrome, and TT401/402 for the treatment of diabetes. The Company is engaged in developing disease-modifying small molecule therapeutics that act by preventing the formation of and breaking down amyloid beta peptide aggregates. TT-401 provides glycemic control and other effects, including weight loss.

Officers and directors

Tony F. Cruz Ph.D. Chairman of the Board, Chief Executive Officer
Bio & Compensation  - Reuters
Nicole Rusaw Chief Financial Officer
Age: 39
Bio & Compensation  - Reuters
Carl Damiani Chief Operating Officer, Vice President - Business Development
Age: 39
Bio & Compensation  - Reuters
Bruce Connop Vice President - Non-Clinical & Pharmaceutical Development
Age: 43
Bio & Compensation  - Reuters
Aleksandra Pastrak Vice President - Clinical Development and Medical Officer
Age: 46
Bio & Compensation  - Reuters
Louis Alexopoulos Secretary
Bio & Compensation  - Reuters
Michael Richard Dwyer Ashton Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Paul Baehr Independent Director
Age: 69
Bio & Compensation  - Reuters
Christopher M. Henley Independent Director
Age: 52
Bio & Compensation  - Reuters
Gary W. Pace Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters